News coverage about Stellar Biotechnologies (NASDAQ:SBOT) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.0292741435138 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Stellar Biotechnologies (NASDAQ:SBOT) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.34 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at

About Stellar Biotechnologies

Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.

Insider Buying and Selling by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)

Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.